Affymax (NASDAQ:AFFY)’s fourth quarter results out – SVM, DVAX

Boston, MA 04/08/2013 (wallstreetpr) – Affymax (NASDAQ:AFFY) closed at $1.16 on Friday’s stock market, a drop by 0.01% from its previous close of $1.17. The company is a small cap, with a potential of 46.46M in revenues as reported yesterday. The earnings per share were -1.52, with a profit margin of -65.57% when NASDAQ closed. Affymax couldn’t gear up to its target share price of 2.02, and sold dirt cheap at only $1.25. The company has witnessed a significant fall in its stock prices recently, contributing to its falling revenue generation. The company also reported its fourth quarter and year end 2012 financial results, affirming why the shares are falling consistently. The current stock trend is not viewed positively by the investors, resulting in a further drop in share selling prices.

Silvercorp Metals (NASDAQ:SVM) was trading at $3.37 when NASDAQ closed on Friday, a  0.04% drop from its previous day closing share price. The market cap achieved was 597.73M, with only 0.18 earnings per share. The profit margin remained good despite of a fall in the share prices and floated around 24.75%. Investors were speculating a price of $7.42, but the shares could only attain $3.50. The closing share price yesterday was pretty close to its 52 week low of $3.35. Specializing in silver and other precious metals, Silvercorp provide the latest update about its class action and defamation case that was primarily considered the reason behind its dropping share price. Furthermore, it is among the top five toxic stocks that investors should sell in April.

Dynavax Technologies Corporation (NASDAQ:DVAX) is a drug manufacturing company in the United States, which traded up by 1.27% on Friday’s stock market. Its shares closed at a price of $2.39, which is higher than its previous close of $2.36. Simultaneously, Dynavax gained a market cap of 413.31M, with earnings per share of $-0.33. Despite of the growth, the profit margins floated low at -277.60%. Furthermore, the stocks failed to meet the investors’ speculation of $4.17 price per share. Of late, the company announced its plan to hire for strategic global operations. According to market analysts, Dynavax is a lucrative buy.

For consideration of being featured on WallstreetPR, contact:

Please make sure to read and completely understand our disclaimer at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at

Published by Brendan Byrne

While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email ( or his Google+ page (